Immunosuppressive antimetabolite; also active as disease modifying antirheumatic drug (DMARD). Metabolized in vivo to 6-mercaptopurine, q.v. Prepn: G. H. Hitchings, G. B. Elion, US 3056785 (1962 to Burroughs Wellcome). Metabolism and pharmacokinetics: T. L. Ding, L. Z. Benet, Drug Metab. Dispos. 7, 373 (1979). Carcinogenicity studies: P. S. Mitrou et al., Arzneim.-Forsch. 29, 483, 662 (1979). HPLC determn in plasma: E. C. Van Os et al., J. Chromatogr. B 679, 147 (1996). Clinical trial in rheumatoid arthritis: R. F. Wilkens, D. Stablein, J. Rheumatol. 23, Suppl. 44, 64 (1996). Comprehensive description: W. P. Wilson, S. A. Benezra, Anal. Profiles Drug Subs. 10, 29-53 (1981). Review of clinical efficacy in renal transplantation: G. L. C. Chan et al., Pharmacotherapy 7, 165-177 (1987); in multiple sclerosis: C. Confavreux, T. Moreau, Mult. Scler. 1, 379-384 (1996); in inflammatory bowel disease: W. J. Sandborn, Scand. J. Gastroenterol. 33, Suppl. 225, 92-99 (1998).
Immunosuppressant; antirheumatic.
Antiarthritic/Antirheumatic; Immunosuppressant